Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Author Department

Medicine

Document Type

Article, Peer-reviewed

Publication Date

9-1-2005

Abstract

BACKGROUND: In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had s

Publication ISSN

0884-8734

Share

COinS